We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BF.B icon
201
Brown-Forman Class B
BF.B
$12B
$317K ﹤0.01%
4,600
-1,000
-18% -$73.3K
MTD icon
202
Mettler-Toledo International
MTD
$26.8B
$312K ﹤0.01%
270
-150
-36% -$174K
POOL icon
203
Pool Corp
POOL
$6.7B
$311K ﹤0.01%
900
-300
-25% -$104K
EA icon
204
Electronic Arts
EA
$52.4B
$307K ﹤0.01%
2,270
-1,000
-31% -$139K
VRSK icon
205
Verisk Analytics
VRSK
$26.4B
$307K ﹤0.01%
1,739
-750
-30% -$137K
ANSS
206
DELISTED
Ansys
ANSS
$306K ﹤0.01%
900
-340
-27% -$121K
JD icon
207
JD.com
JD
$40.8B
$304K ﹤0.01%
3,600
-1,700
-32% -$156K
CSGP icon
208
CoStar Group
CSGP
$11.3B
$288K ﹤0.01%
3,500
-1,500
-30% -$130K
IPGP icon
209
IPG Photonics
IPGP
$3.89B
$285K ﹤0.01%
1,350
-1,000
-43% -$227K
CTLT
210
DELISTED
CATALENT, INC.
CTLT
$284K ﹤0.01%
2,700
-2,000
-43% -$223K
RVTY icon
211
Revvity
RVTY
$12.3B
$282K ﹤0.01%
2,200
-1,300
-37% -$180K
CYBR
212
DELISTED
CyberArk
CYBR
$272K ﹤0.01%
2,100
-2,200
-51% -$333K
STNE icon
213
StoneCo
STNE
$2.62B
$263K ﹤0.01%
4,300
-3,200
-43% -$250K
MELI icon
214
Mercado Libre
MELI
$91.3B
$250K ﹤0.01%
170
-170
-50% -$288K
ICPT
215
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$185K ﹤0.01%
8,000
– –
VYGR icon
216
Voyager Therapeutics
VYGR
$187M
$150K ﹤0.01%
31,800
-2,680,283
-99% -$18.3M
ADI icon
217
Analog Devices
ADI
$181B
– –
-4,100
Closed -$606K
ALV icon
218
Autoliv
ALV
$8.6B
– –
-6,800
Closed -$626K
AVNT icon
219
Avient
AVNT
$3.45B
– –
-13,600
Closed -$548K
BLKB icon
220
Blackbaud
BLKB
$1.5B
– –
-4,107
Closed -$236K
BR icon
221
Broadridge
BR
$17.2B
– –
-3,400
Closed -$521K
CDTX
222
DELISTED
Cidara Therapeutics
CDTX
– –
-141,125
Closed -$5.64M
CHRS icon
223
Coherus Oncology
CHRS
$217M
– –
-149,000
Closed -$2.59M
DGX icon
224
Quest Diagnostics
DGX
$25.1B
– –
-6,749
Closed -$804K
LKFT
225
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-9,500
Closed -$940K
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.